Newsroom

Logo
News
The European Research Council (ERC) awards three scientists from the Helmholtz Centre for Infection Research (HZI) with an ERC Starting Grant. The grants of up to 1.5 million Euros over a period of five years will be awarded to Jun Prof Neva Caliskan from the Helmholtz Institute for RNA-based Infection Research (HIRI), Jun Prof Gregor Fuhrmann from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Prof Yang Li from the Centre for Individualised Infection Medicine (CiiM).
03.09.2020
Bei Bakterien der Gattung Salmonella ist HIRI-Forschern erstmals die RNA-Einzelzellsequenzierung gelungen
News
Bacteria show a wide range of capabilities in withstanding antibiotic treatment or attack by our immune system, which are great challenges in infection research. Scientists at the Würzburg-based Helmholtz Institute for RNA-based Infection Research (HIRI), a site of the Helmholtz Centre for Infection Research (HZI), have developed a novel approach to reading the activity of hundreds of genes in an individual bacterium by sequencing its RNA. This groundbreaking work was just published in the journal Nature Microbiology. Using bacterial single-cell RNA sequencing it might be possible to elucidate the tricks bacteria use to develop resistance and close these loopholes with tailored drugs.
18.08.2020
CARE-Consortium
News
The new consortium CARE (Corona Accelerated R&D in Europe), supported by the Innovative Medicines Initiative (IMI) public-private partnership, announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totalling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the UK and the US, and is led by VRI-Inserm (French National Institute of Health and Medical Research, Paris, France), Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Beerse, Belgium), and Takeda Pharmaceuticals International AG (Zurich, Switzerland). It integrates partners’ COVID-19 projects ongoing since February 2020.
18.08.2020
3D-Darstellung von Coronavirus-Partikeln
News
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction – rather, the immune response is caught in a continuous loop of activation and inhibition. Experts from Charité – Universitätsmedizin Berlin, the University of Bonn, the German Center for Neurodegenerative Diseases (DZNE), the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF), along with colleagues from a nationwide research network, present these findings in the scientific journal Cell.
06.08.2020
Logo
News
Who has overcome an infection with the virus without noticing, and how many people have already produced protective antibodies against the new coronavirus? Various antibody studies are now under way that will provide information on immunity or seroprevalence in the population. However, in order to compare these studies in a timely and reliable manner and provide a comprehensive evaluation, the German Center for Infection Research (DZIF) is building a platform that gathers the methodology and results of the tests and makes the data available to interested researchers. The project “LEOSS.sero-survey” will be led by scientists at the Helmholtz Centre for Infection Research (HZI) and implemented in collaboration with Helmholtz Federated IT Services (HIFIS).
03.08.2020
News
The intestinal microbiota plays a central role for human physiology. Traditional studies have focused on the changes in microbiota composition under diverse conditions. Recently, efforts shifted towards understanding the molecular biology of intestinal bacteria. The species Bacteroides thetaiotaomicron (B. theta) has emerged as a model organism for human intestinal microbiota research. Scientists at the Helmholtz Institute for RNA-based Infection Research (HIRI) have captured a detailed map of RNAs and their activities in these anaerobic bacteria. The HIRI is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Julius-Maximilians-Universität Würzburg. The results can be browsed in an online database and were published in the journal Nature Communications.
17.07.2020

HZI in the media

Vor allem durch die Coronapandemie sind Forschende des Helmholtz-Zentrums für Infektionsforschung in den vergangenen Jahren bundesweit bekannt geworden. Auf welche Themen die Einrichtung für die Zukunft setzt.

20.03.2026
|
Deutsches Ärzteblatt

... beschäftigt sich daneben unter dem Dach des Helmholtz Institutes für Pharmazeu­tische Forschung Saarland (HIPS) ...

18.03.2026
|
Biermann Medizin

... Ausbau von Produktions- und Vermarktungskapazitäten.

 

Das Helmholtz-Zentrum für Infektionsforschung HZI begrüßt den Erhalt der GMP- ...

18.03.2026
|
Bionity.COM

... der Universität zu Lübeck, des Helmholtz-Zentrums für Infektionsforschung (HZI) in Braunschweig, der Medizinischen Hochschule Hannover ...

17.03.2026
|
Biermann Medizin

Vorsorge Das Coronavirus hält die Welt nicht mehr in Atem. Doch was, wenn ein ­anderer gefährlicher Erreger auftaucht? So wappnet sich unser Gesundheitssystem

16.03.2026
|
Apotheken Umschau

... stumpfen ab“, erklärt Marc Brönstrup vom Helmholtz-Zentrum für Infektionsforschung in Braunschweig. Neue Antibiotika sind dringend ...

14.03.2026
|
ARD Mediathek

... der Medizinischen Hochschule Hannover und dem Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig neue Wirkstoffe ...

13.03.2026
|
MTA Dialog

... späten 1990ern hob sie der am Saarbrücker Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) tätige ...

08.03.2026
|
Saarbrücker Zeitung

European institutions, including Germany’s Helmholtz Institute for RNA-based Infection Research, Helmholtz Center for Infection Research,

06.03.2026
|
Clinical Lab Products

Die Zellen kontrollieren die Reaktion des Immunsystems und verhindern Schäden durch Selbstangriffe. Forschende arbeiten daran, sie zur Therapie einzusetzen.

05.03.2026
|
NDR Norddeutscher Rundfunk

Nachwuchsgruppe „Nanoinfektionsbiologie“ am HZI. Diese Lücke soll das Projekt ONEMUC (Respiratorischer Mukus als One Health-Schnittstelle) ...

03.03.2026
|
DeutschesGesundheitsPortal

Hochschule Hannover (MHH) und des Helmholz-Zentrums für Infektionsforschung (HZI) erforschen im Rahmen des Projektes StopPSC ( ...

03.03.2026
|
Biermann Medizin

Register now for the HZI-Newsletter